All In Biotech

Drug Trial Radar · NCT06785727

StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jan 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 612 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

612

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Dec 1, 2028

Study completion Jul 1, 2029

Sponsor

Lead sponsor
Prof. dr. Nathalie van der VeldeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
VU University of Amsterdam
First posted
Jan 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 70 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST - RCT, the investigators will assess the impact of starting versus not starting a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and Major Adverse Cardiovascular Events (MACE) free survival during a two-year follow-up period.

Conditions

  • Ischemic Stroke
  • Transient Ischemic Attack

Interventions

  • Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)Drug

    The intervention group receives statin treatment following the current "Herseninfarct en Hersenbloeding" guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health-Related Quality of Life (HrQoL)Time frame: 3, 6, 12, 18, 24 (and 36) months.
  2. Major Adverse Cardiovascular Events (MACE) free survivalTime frame: 3, 6, 12, 18, 24 (and 36) months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.